Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 19, 2026 09:00 ET | Source: BVI Medical, Inc.

BVI Appoints Jim Hollingshead as President & Chief Executive Officer

BVI appoints Jim Hollingshead as President & CEO, succeeding Shervin Korangy, to lead the company’s next phase of global growth and innovation.
January 16, 2026 08:49 ET | Source: CMI

Vision Care Market Size to Surpass USD 169.38 Billion by 2032, Driven by Rising Vision Disorders | Coherent Market Insights

Burlingame, CA, Jan. 16, 2026 (GLOBE NEWSWIRE) -- The Global Vision Care Market is estimated to be valued at USD 104.11 Bn in 2025 and is expected to reach USD 169.38 Bn by 2032, exhibiting a...
January 15, 2026 16:05 ET | Source: PainReform Ltd

PainReform Ltd. Changes Name to PRF Technologies Ltd. Reflecting Expansion into Diversified Healthcare and AI-Driven Energy Platforms

TEL AVIV, Israel, Jan. 15, 2026 (GLOBE NEWSWIRE) -- PRF Technologies Ltd. (Nasdaq: PRFX) (“PRF” or the “Company”) (formerly “PainReform”) today announced its corporate name change to PRF...
January 15, 2026 10:38 ET | Source: Research and Markets

Uveitis Global Clinical Trials Review Report 2025: Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End Point Status

Dublin, Jan. 15, 2026 (GLOBE NEWSWIRE) -- The "Uveitis - Global Clinical Trials Review, 2025" report has been added to ResearchAndMarkets.com's offering.The clinical trial report provides an...
January 15, 2026 08:15 ET | Source: Ocugen

Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. controlThere are no OCU410-related serious adverse events reported across the Phase 1 and Phase 2...
January 14, 2026 09:51 ET | Source: Research and Markets

$191.2 Million Achromatopsia Market Outlook, 2026-2032, Featuring Adverum Biotechnologies, Homology Medicines, Mattel, REGENXBIO, Sanofi and More

Dublin, Jan. 14, 2026 (GLOBE NEWSWIRE) -- The "Achromatopsia Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering. The Achromatopsia Market is experiencing...
January 14, 2026 09:46 ET | Source: Research and Markets

Artificial Iris Market Outlook 2026-2032: A $36.92 Million Global Opportunity

Dublin, Jan. 14, 2026 (GLOBE NEWSWIRE) -- The "Artificial Iris Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering. The Artificial Iris Market has shown...
January 14, 2026 09:09 ET | Source: Spherix Global Insights

Spherix Global Insights Highlights Evolving PD-1 Landscape as Subcutaneous Use Grows and Biosimilars Approach across Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma

Exton, PA, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Spherix Global Insights reports new findings from its inaugural Market Dynamix™: PD-1 Inhibition in Solid Tumors (US) study, based on quantitative and...
January 13, 2026 10:27 ET | Source: Research and Markets

AI Optical Coherence Tomography Market Opportunities to 2029 & 2034 by Type, Technology, Application and Region

Dublin, Jan. 13, 2026 (GLOBE NEWSWIRE) -- The "Artificial Intelligence (AI) Optical Coherence Tomography (OCT) Market Report 2025" has been added to ResearchAndMarkets.com's offering. The...
January 13, 2026 07:00 ET | Source: Ocugen

Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data

MALVERN, Pa., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced...